Selective histone deacetylase inhibition as a therapeutically relevant strategy in H3K27M-glioma.

Saved in:
Bibliographic Details
Title: Selective histone deacetylase inhibition as a therapeutically relevant strategy in H3K27M-glioma.
Authors: Groves A; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.; Division of Hematology/Oncology, University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, USA., Kirkland OO; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.; Department of Chemistry & Chemical Biology, Harvard University, Cambridge, Massachusetts, USA., Cascio CL; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA., Wang X; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Heaslip C; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Marques JG; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA., Song C; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Poetschke R; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA., Wang T; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Chin DH; Department of Genetics and Genome Sciences, Case Western University School of Medicine, Cleveland, Ohio, USA., Asante Y; Department of Genetics and Genome Sciences, Case Western University School of Medicine, Cleveland, Ohio, USA., Liu Q; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Kim H; Department of Genetics and Genome Sciences, Case Western University School of Medicine, Cleveland, Ohio, USA., Gu S; Department of Genetics and Genome Sciences, Case Western University School of Medicine, Cleveland, Ohio, USA., Trissal M; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA., Labelle J; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA., Cruzeiro GAV; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA., Jones KL; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Cameron AB; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Clark LM; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Leeper B; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Nguyen QD; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Gryder BE; Department of Genetics and Genome Sciences, Case Western University School of Medicine, Cleveland, Ohio, USA., Filbin MG; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA., Qi J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Source: Neuro-oncology [Neuro Oncol] 2026 Jun 25. Date of Electronic Publication: 2026 Jun 25.
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1523-5866
DOI:10.1093/neuonc/noag142